Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lowered its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 78.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 14,917 shares of the company’s stock after selling 53,684 shares during the quarter. SG Americas Securities LLC’s holdings in Stoke Therapeutics were worth $183,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in STOK. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in Stoke Therapeutics by 426.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock valued at $18,741,000 after purchasing an additional 1,123,500 shares in the last quarter. Lynx1 Capital Management LP boosted its holdings in shares of Stoke Therapeutics by 40.3% in the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock valued at $70,052,000 after buying an additional 1,488,371 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Stoke Therapeutics by 16.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after buying an additional 1,994 shares in the last quarter. Millennium Management LLC grew its position in shares of Stoke Therapeutics by 528.6% in the 2nd quarter. Millennium Management LLC now owns 289,067 shares of the company’s stock valued at $3,905,000 after buying an additional 243,083 shares during the last quarter. Finally, Marshall Wace LLP lifted its position in Stoke Therapeutics by 550.1% in the second quarter. Marshall Wace LLP now owns 1,161,037 shares of the company’s stock valued at $15,686,000 after acquiring an additional 982,451 shares during the last quarter.

Insider Buying and Selling

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the sale, the insider now owns 8,906,181 shares of the company’s stock, valued at approximately $125,131,843.05. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Thursday, August 8th. HC Wainwright restated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, September 11th. Wedbush reiterated an “outperform” rating and issued a $17.00 price objective on shares of Stoke Therapeutics in a research note on Thursday, July 11th. Leerink Partners initiated coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 target price on the stock. Finally, Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $20.83.

Stoke Therapeutics Trading Down 3.7 %

NASDAQ:STOK opened at $12.06 on Thursday. The stock’s 50 day simple moving average is $13.58 and its 200-day simple moving average is $13.70. Stoke Therapeutics, Inc. has a 12-month low of $3.35 and a 12-month high of $17.58. The firm has a market cap of $634.96 million, a P/E ratio of -5.53 and a beta of 0.97.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.11. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. The company had revenue of $4.83 million for the quarter, compared to analysts’ expectations of $3.33 million. Research analysts forecast that Stoke Therapeutics, Inc. will post -2.1 EPS for the current fiscal year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.